EUR 13.0
(0.78%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 11.92 Million GBP | 1.99% |
2022 | 11.68 Million GBP | -20.49% |
2021 | 14.7 Million GBP | -17.45% |
2020 | 17.8 Million GBP | 1441.9% |
2019 | 1.15 Million GBP | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 Q4 | 11.92 Million GBP | 3.17% |
2023 FY | 11.92 Million GBP | 1.99% |
2023 Q2 | 11.55 Million GBP | -1.14% |
2022 FY | 11.68 Million GBP | -20.49% |
2022 Q4 | 11.68 Million GBP | -5.62% |
2022 Q2 | 12.38 Million GBP | -15.76% |
2021 FY | 14.7 Million GBP | -17.45% |
2021 Q4 | 14.7 Million GBP | -3.95% |
2021 Q2 | 15.3 Million GBP | -14.05% |
2020 Q4 | 17.8 Million GBP | 1.18% |
2020 FY | 17.8 Million GBP | 1441.9% |
2020 Q2 | 17.6 Million GBP | 0.0% |
2019 FY | 1.15 Million GBP | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
BioNTech SE | 23 Billion EUR | 99.948% |
CureVac N.V. | 788.89 Million EUR | 98.489% |
Biotest Aktiengesellschaft | 1.44 Billion EUR | 99.175% |
Biotest Aktiengesellschaft | 1.44 Billion EUR | 99.175% |
BRAIN Biotech AG | 70.93 Million EUR | 83.194% |
Formycon AG | 890.36 Million EUR | 98.661% |
Heidelberg Pharma AG | 70.35 Million EUR | 83.054% |
Medigene AG | 31.71 Million EUR | 62.41% |